ORKA — Oruka Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 907654 ·
Last close
$96.32
Market Cap
$6.53B
52W High
$115.52
52W Low
$25.23
ADV30
977,146
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -62,136,000 | -49,965,000 | 1,231,026,000 | 191,519,000 | 33,875,000 |
| Jun 2026 | 0 | — | -50,107,000 | -41,206,000 | 1,139,394,000 | 268,470,000 | 27,776,000 |
| Mar 2026 | 0 | — | -36,434,000 | -31,820,000 | 504,480,000 | 49,520,000 | 20,691,000 |
| Dec 2025 | 0 | — | -34,431,000 | -29,583,000 | 488,617,000 | 46,935,000 | 19,618,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-123,643,000
Investing CF
$-606,805,000
Financing CF
$830,714,000
CapEx
$-318,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.21
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-312,148,000
Inventory
—
Receivables
—
ST Investments
$728,758,000
EBIT TTM
$-178,260,000
Pretax Income TTM
$-152,574,000
Interest Exp TTM
$0
Analysts
12
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,051,000 | -105,433,000 | 488,617,000 | 19,618,000 | 468,999,000 | -88,210,000 |
| Dec 2024 | — | — | — | 396,019,000 | 16,729,000 | 379,290,000 | — |
TTM Snapshot
Revenues TTM
$22,184,000
NetIncome TTM
$-132,886,000
OpCashFlow TTM
—
Assets (Latest)
$1,139,394,000
Forward EPS
$-2.88
Max Pain — expiry 2027-02-19
max pain strike: $75.00 · spot: $95.74 · call oi: 47 · put oi: 3,003Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BLTE | BELITE BIO, INC | $6.35B | $157.72 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $6.08B | $42.99 | — |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.00B | $91.95 | — |
| AXSM | Axsome Therapeutics, Inc. | $7.15B | $135.95 | — |
| ABVX | Abivax S.A. | $7.16B | $82.10 | — |
News headlines (Yahoo Finance, 1h cache)
Phase 2 Psoriasis Results Could Be A Big Moment For Oruka Therapeutics Stock (ORKA)
2026-11-11 01:17 · Yahoo
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-09 21:04 · Yahoo
Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study
2026-10-27 03:02 · Yahoo
Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift”
2026-10-26 17:45 · Yahoo
Oruka’s Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months
2026-10-26 16:07 · Yahoo
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
2026-10-26 11:00 · Yahoo
Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist
2026-10-26 02:28 · Yahoo
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
2026-10-25 16:00 · Yahoo
Oruka Therapeutics (ORKA) Stock May Be Trading On A Rich Premium To Book Value
2026-10-20 06:10 · Yahoo
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says
2026-09-24 17:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.